Business Description
Ascentage Pharma Group International
ISIN : KYG0519B1023
Description
Financial Strength
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.6 | |||||
Equity-to-Asset | 0.02 | |||||
Debt-to-Equity | 29.72 | |||||
Debt-to-EBITDA | -6.63 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -0.97 | |||||
Beneish M-Score | -1.6 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 133 | |||||
3-Year EBITDA Growth Rate | 6.5 | |||||
3-Year EPS without NRI Growth Rate | 1 | |||||
3-Year FCF Growth Rate | 13.8 | |||||
3-Year Book Growth Rate | -62.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 83.54 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 57.52 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 88.19 | |||||
9-Day RSI | 84.02 | |||||
14-Day RSI | 79.97 | |||||
6-1 Month Momentum % | 44.8 | |||||
12-1 Month Momentum % | 39.23 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.44 | |||||
Quick Ratio | 1.42 | |||||
Cash Ratio | 1.14 | |||||
Days Inventory | 137.88 | |||||
Days Sales Outstanding | 38.69 | |||||
Days Payable | 973.53 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.7 | |||||
Shareholder Yield % | -3.92 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 96.94 | |||||
Operating Margin % | -36.92 | |||||
Net Margin % | -40.77 | |||||
FCF Margin % | -87.09 | |||||
ROE % | -101.97 | |||||
ROA % | -13.1 | |||||
ROIC % | -18.26 | |||||
3-Year ROIIC % | -13.36 | |||||
ROC (Joel Greenblatt) % | -39.4 | |||||
ROCE % | -15.23 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 12.2 | |||||
PB Ratio | 176.32 | |||||
EV-to-EBIT | -41.55 | |||||
EV-to-EBITDA | -45.42 | |||||
EV-to-Revenue | 13.82 | |||||
EV-to-FCF | -15.71 | |||||
Earnings Yield (Greenblatt) % | -2.41 | |||||
FCF Yield % | -6.77 |